Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and health care issues, finds that the continued uptake of currently marketed tumor necrosis factor-alpha (TNF-alpha) inhibitors and the launch and uptake of novel biological agents will drive robust growth in the rheumatoid arthritis treatment market in the United States, United Kingdom, France, Germany, Italy, Spain, and Japan. Major market sales for treating the disease will nearly double, reaching more than $10 billion in 2015.

According to the new Pharmacor report Rheumatoid Arthritis, the driving force behind market growth will be the continued uptake of currently marketed, high-priced TNF-alpha inhibitors, especially Amgen/Wyeth/Takeda's Enbrel (etanercept), and Abbott/Eisai's Humira (adalimumab). Market growth will also be driven by the launch and uptake of novel, expensive biological agents including Bristol-Myers Squibb's Orencia (abatacept), Biogen Idec/Genentech/Chugai/Zenyaku Kogyo's Rituxan (rituximab), and Roche's MabThera (rituximab).

"We expect TNF-alpha inhibitors to remain the most widely prescribed biological agents for the treatment of rheumatoid arthritis because they have the most established efficacy and safety records of any biological agents approved for the disease," said Melissa Stolper, analyst at Decision Resources, Inc. "Recently launched treatments, specifically abatacept and rituximab, represent important advances in rheumatoid arthritis pharmacotherapy owing to their novel mechanisms of action. However, these agents will likely be used as follow-on therapies for patients whose disease fails to respond adequately to TNF-alpha inhibition."

About Rheumatoid Arthritis

Rheumatoid arthritis is characterized by chronic joint inflammation that typically results in progressive, irreversible joint damage and occasionally, joint deformation. The biological agents Enbrel, Centocor/Schering-Plough/Tanabe's Remicade (infliximab), and Humira are the top-selling therapies to treat the disease, with combined major-market sales totaling $4.6 billion in 2005.

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

United Eyes Pennsylvania as Next Target for Health Plan Membership Growth, According to HealthLeaders-InterStudy

View Now